CN116916909A - 用于治疗睡眠呼吸暂停的瑞波西汀和毒蕈碱受体拮抗剂(mra)的组合 - Google Patents

用于治疗睡眠呼吸暂停的瑞波西汀和毒蕈碱受体拮抗剂(mra)的组合 Download PDF

Info

Publication number
CN116916909A
CN116916909A CN202280018649.9A CN202280018649A CN116916909A CN 116916909 A CN116916909 A CN 116916909A CN 202280018649 A CN202280018649 A CN 202280018649A CN 116916909 A CN116916909 A CN 116916909A
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
acceptable salt
reboxetine
oxybutynin
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280018649.9A
Other languages
English (en)
Chinese (zh)
Inventor
L·G·米勒
R·法卡斯
L·塔兰托-蒙特穆罗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epuning Delaware
Original Assignee
Epuning Delaware
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epuning Delaware filed Critical Epuning Delaware
Publication of CN116916909A publication Critical patent/CN116916909A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN202280018649.9A 2021-03-04 2022-03-03 用于治疗睡眠呼吸暂停的瑞波西汀和毒蕈碱受体拮抗剂(mra)的组合 Pending CN116916909A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163156463P 2021-03-04 2021-03-04
US63/156,463 2021-03-04
PCT/US2022/018604 WO2022187420A1 (en) 2021-03-04 2022-03-03 Combination of reboxetine and a muscarinic receptor antagonist (mra) for use in treating sleep apnea

Publications (1)

Publication Number Publication Date
CN116916909A true CN116916909A (zh) 2023-10-20

Family

ID=80999274

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280018649.9A Pending CN116916909A (zh) 2021-03-04 2022-03-03 用于治疗睡眠呼吸暂停的瑞波西汀和毒蕈碱受体拮抗剂(mra)的组合

Country Status (8)

Country Link
US (1) US20240139200A1 (https=)
EP (1) EP4301353A1 (https=)
JP (1) JP2024508498A (https=)
KR (1) KR20230154186A (https=)
CN (1) CN116916909A (https=)
AU (1) AU2022231133A1 (https=)
CA (1) CA3210092A1 (https=)
WO (1) WO2022187420A1 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
CA2431041A1 (en) * 2001-01-02 2002-07-11 Pharmacia & Upjohn Company New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
US20070196481A1 (en) * 2002-07-25 2007-08-23 Amidon Gregory E Sustained-release tablet composition
GEAP202416602A (en) * 2017-04-28 2024-10-10 Brigham & Womens Hospital Inc Methods and compositions for treating sleep apnea
KR102874891B1 (ko) * 2018-01-30 2025-10-21 애프니메드, 인코포레이티드 (델라웨어) 수면 무호흡증을 치료하기 위한 방법 및 조성물

Also Published As

Publication number Publication date
CA3210092A1 (en) 2022-09-09
EP4301353A1 (en) 2024-01-10
AU2022231133A1 (en) 2023-09-21
US20240139200A1 (en) 2024-05-02
JP2024508498A (ja) 2024-02-27
KR20230154186A (ko) 2023-11-07
WO2022187420A1 (en) 2022-09-09

Similar Documents

Publication Publication Date Title
US20230201224A1 (en) 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
CN110799181A (zh) 用于治疗睡眠呼吸暂停的方法和组合物
EA002554B1 (ru) Применение кабэрголина при лечении синдрома усталых ног
CN118384147A (zh) 用于治疗睡眠呼吸暂停的方法和组合物
US20240075035A1 (en) Methods and compositions for treating sleep apnea
US20240277719A1 (en) Norepinephrine reuptake inhibitors for treating sleep apnea
CN117062626A (zh) 用于治疗睡眠呼吸暂停的方法和组合物
CN116916909A (zh) 用于治疗睡眠呼吸暂停的瑞波西汀和毒蕈碱受体拮抗剂(mra)的组合
US20230135373A1 (en) Methods and compositions for treating sleep apnea
KR20240053061A (ko) 수면 무호흡증을 치료하기 위한 방법 및 조성물
CN117615764A (zh) 用于治疗睡眠呼吸暂停的去甲肾上腺素再摄取抑制剂
KR20250057804A (ko) 수면 무호흡증을 치료하기 위한 방법 및 조성물
US20250302814A1 (en) Methods and compositions for treating sleep apnea
US20250009720A1 (en) Methods and compositions for treating sleep apnea
WO2024220343A1 (en) Combination of a norepinephrine reuptake inhibitor and a melatonin receptor agonist for use in treating sleep apnea
WO2026052068A1 (zh) 药物组合物的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination